Creazione di una rete clinica italiana per l’atrofia muscolare spinale (SMA)
- 4.2 Anni 2014/2018
 - 215.598€ Totale Fondi
 
Seppure non esista a tutt’oggi una cura per la atrofia muscolare spinale (SMA), per la prima volta sono stati identificati degli approcci farmacologici con grosse potenzialità per migliorare il decorso clinico di questa malattia. Alcuni di questi approcci hanno già completato la fase preclinica e stanno entrando in fase clinica. Uno dei problemi più grossi nel campo di malattie rare come la SMA è la necessità di dover condurre studi multicentrici, spesso internazionali, per il numero limitato di bambini presenti in ogni centro. Lo studio qui proposto ha l’obiettivo di creare una rete di centri clinici in Italia esperti in SMA. Hanno aderito all’iniziativa 13 centri clinici che già lavorano insieme nel campo di un’altra malattia muscolare, la distrofia di Duchenne. Sfruttando la rete esistente di medici e fisioterapisti, si propone quindi di investire nel campo della SMA. L’obiettivo è di uniformare gli standard di cura e di utilizzare le misure usate a livello internazionale per contribuire alla raccolta di dati internazionali. Questo consentirà di accelerare il processo di perfezionamento delle misure di valutazione da usare e, allo stesso tempo rendere i centri italiani idonei a partecipare ai nuovi studi che arrivano dall’estero. Questo processo si effettuerà organizzando un sistema che garantisca che: a) tutti i centri terziari neuromuscolari abbiano lo stesso training; b) tutti i centri usino le stesse misure; c) la raccolta dati sia più veloce; d) venga creato un sistema di raccolta dati unico che faciliti l'accesso e l'analisi dei dati (common data elements) associato all’esistente registro SMA (www.registronmd.it), che attualmente raccoglie i dati di 350 pazienti con SMA.
Pubblicazioni Scientifiche
- 2021-03-01 ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY 
Type I SMA "new natural history": long-term data in nusinersen-treated patients
 - 2021-08-01 ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY 
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy
 - 2022-03-01 ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY 
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy
 - 2020-12-01 ANNALS OF NEUROLOGY 
Clinical Variability in Spinal Muscular Atrophy TypeIII
 - 2017-02-23 BMC NEUROLOGY 
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy
 - 2021-02-01 EUROPEAN JOURNAL OF NEUROLOGY 
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen
 - 2022-05-01 GACETA SANITARIA 
Health care costs of breast, prostate, colorectal and lung cancer care by clinical stage and cost component
 - 2023-03-01 JOURNAL OF CLINICAL MEDICINE 
2-Year Change in Revised Hammersmith Scale Scores in a Large Cohort of Untreated Paediatric Type 2 and 3 SMA Participants
 - 2020-04-01 JOURNAL OF NEUROLOGY 
MRI patterns of muscle involvement in type 2 and 3 spinal muscular atrophy patients
 - 2024-01-01 JOURNAL OF NEUROMUSCULAR DISEASES 
Disease Trajectories in the Revised Hammersmith Scale in a Cohort of Untreated Patients with Spinal Muscular Atrophy types 2 and 3
 - 2015-09-01 MUSCLE & NERVE 
Old measures and new scores in spinal muscular atrophy patients
 - 2017-06-01 MUSCLE & NERVE 
REVISED UPPER LIMB MODULE FOR SPINAL MUSCULAR ATROPHY: DEVELOPMENT OF A NEW MODULE
 - 2019-04-01 MUSCLE & NERVE 
Revised upper limb module for spinal muscular atrophy: 12 month changes
 - 2021-11-01 MUSCLE & NERVE 
Different trajectories in upper limb and gross motor function in spinal muscular atrophy
 - 2018-08-21 NEUROLOGY 
An observational study of functional abilities in infants, children, and adults with type 1 SMA
 - 2019-09-24 NEUROLOGY 
Long-term progression in type II spinal muscular atrophy A retrospective observational study
 - 2013-08-01 NEUROMUSCULAR DISORDERS 
Six minute walk test in type III spinal muscular atrophy: A 12 month longitudinal study
 - 2015-03-01 NEUROMUSCULAR DISORDERS 
Upper limb module in non-ambulant patients with spinal muscular atrophy: 12 month changes
 - 2016-02-01 NEUROMUSCULAR DISORDERS 
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials
 - 2017-10-01 NEUROMUSCULAR DISORDERS 
6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction
 - 2018-01-01 NEUROMUSCULAR DISORDERS 
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy
 - 2018-03-01 NEUROMUSCULAR DISORDERS 
Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics
 - 2019-10-01 NEUROMUSCULAR DISORDERS 
Development of an academic disease registry for spinal muscular atrophy
 - 2020-09-01 NEUROMUSCULAR DISORDERS 
Age and baseline values predict 12 and 24-month functional changes in type 2 SMA
 - 2021-07-01 NEUROMUSCULAR DISORDERS 
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen
 - 2022-01-01 NEUROMUSCULAR DISORDERS 
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes
 - 2013-03-20 ORPHANET JOURNAL OF RARE DISEASES 
SMA-EUROPE workshop report: opportunities and challenges in developing clinical trials for spinal muscular atrophy in Europe
 - 2018-10-04 ORPHANET JOURNAL OF RARE DISEASES 
The Italian neuromuscular registry: a coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage
 - 2020-04-05 ORPHANET JOURNAL OF RARE DISEASES 
Longitudinal natural history of type I spinal muscular atrophy: a critical review
 - 2017-02-21 PLOS ONE 
Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool
 - 2018-06-26 PLOS ONE 
Ambulatory function in spinal muscular atrophy: Age-related patterns of progression
 - 2020-03-23 PLOS ONE 
Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey?